EFPIA

The final deadline for publication and submission of reports of transparency disclosures required by the European Federation of Pharmaceutical Industry Associations (EFPIA) arrived on June 30, 2016. Companies have now completed publication of all 2015 ‘transfers of value’ (ToV) to healthcare professionals (HCPs) within the 31 countries that signed on to this initiative. Several changes to the requirements have already been made, and questions and concerns remain for amendments likely to be implemented later this year. Additional changes to the requirements are anticipated later this year. Several countries have lobbied to have local government requirements replace the EFPIA reporting requirement, …

The relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of life-enhancing and life-saving medicines. It is a relationship that we are proud of. At the core of the relationship is sharing knowledge to improve outcomes for patients. We want to ensure that patients and others have confidence that this relationship is open and transparent and this is why the pharmaceutical industry is taking the lead on disclosing details of payments and other benefits in kind made by industry to HCPs and HCOs. This information will be …

Conformément au code de transparence de l’EFPIA, Bayer s’engage à publier tous les transferts de valeurs relatif au développement et à la commercialisation de produits pharmaceutiques sous prescription médicale en lien avec les professionnels et les organismes de santé. Une partie des Transferts de Valeurs publiés pour l’année 2015 à titre d’exemple : FRANCE ITALIE Recherche et Développement 6.011.239 €  4.867.693 € Professionnels de santé (HCP) 4.718.348 €  6.074.765 € Organismes de santé (HCO) 3.374.913 €  12.784.337 € TOTAL 14.104.500 €  23.727.796 € Pour consulter les Transferts de Valeurs des 23 filiales de Bayer soumises à l’EFPIA : Austria Bulgaria …

The identities of hundreds of NHS doctors and officials receiving payments from drugs firms are likely to be kept secret despite the publication of a new “transparency register” this week, the Telegraph can disclose. Up to half of medics and other health service staff working for pharmaceutical companies alongside their day jobs have refused permission for their names to be included in a new online database. The publication of the register follows recent controversy over the practice of NHS staff being paid by drugs companies, with the industry claiming the data would allow the public to see which officials were …

Public disclosure of transfers of value from Janssen to Healthcare Professionals and Healthcare Organisations : Les transferts de valeur concernant des professionnels et organisations de santé français sont également publiés !

Over the next ten days, pharmaceutical companies will be disclosing details of collaborations with health professionals (HCPs) and healthcare organisations (HCOs) across Europe. The figures, which will be available online, underline industry’s investment in European healthcare, enabling the development of new medicines through sharing best clinical practice, exchanging information on how new medicines fit into the patient pathway and shaping the future of clinical research. Director General of EFPIA, Richard Bergström said, “Increasing transparency through the individual disclosure of transfers of value is good for everyone, including healthcare professionals because it builds understanding of this important collaboration.  When pharmaceutical companies …